X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4.9% - What's Next?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report)'s share price was down 4.9% during mid-day trading on Tuesday . The stock traded as low as $5.31 and last traded at $5.07. Approximately 19,287 shares changed hands during trading, a decline of 79% from the average daily volume of 91,837 shares. The stock had previously closed at $5.34.

Analyst Upgrades and Downgrades

A number of brokerages have commented on XFOR. Cantor Fitzgerald reiterated an "overweight" rating and set a $90.00 target price on shares of X4 Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright upped their price objective on X4 Pharmaceuticals from $1.50 to $7.00 and gave the company a "buy" rating in a research report on Friday.

X4 Pharmaceuticals Stock Performance

The stock's 50-day moving average is $7.67 and its 200-day moving average is $13.17. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The stock has a market cap of $21.51 million, a price-to-earnings ratio of -41.33 and a beta of 0.73.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($4.13) by $4.17. The business had revenue of $28.81 million during the quarter, compared to analysts' expectations of $7.03 million. Analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC boosted its holdings in shares of X4 Pharmaceuticals by 233.0% in the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company's stock valued at $134,000 after purchasing an additional 128,148 shares during the last quarter. Atria Wealth Solutions Inc. purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter worth $44,000. Jane Street Group LLC raised its position in shares of X4 Pharmaceuticals by 103.4% in the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company's stock worth $166,000 after buying an additional 126,296 shares during the period. Barclays PLC boosted its holdings in X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company's stock valued at $185,000 after acquiring an additional 183,861 shares during the last quarter. Finally, Northern Trust Corp grew its position in X4 Pharmaceuticals by 2.9% during the fourth quarter. Northern Trust Corp now owns 1,357,539 shares of the company's stock valued at $996,000 after acquiring an additional 37,940 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.